Skip to content
2000
Volume 8, Issue 25
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Raf kinase, an enzyme which acts downstream in the Ras signaling pathway, is involved in cancerous cell proliferation. Thus, small molecule inhibitors of Raf kinase activity may be important agents for the treatment of cancer. A novel class of Raf-1 inhibitors was discovered, using a combination of medicinal and combinatorial chemistry approaches. This effort culminated in the identification of the clinical candidate BAY 43-9006, currently undergoing Phase I clinical trials. The present review summarizes the medicinal chemistry development of ureas as highly potent inhibitors of Raf-1 kinase.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612023393125
2002-11-01
2025-04-15
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612023393125
Loading

  • Article Type:
    Review Article
Keyword(s): bay 43-9006; cancer; diphenyl ureas; raf-1 kinase; ras
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test